The Mechanisms of HSC Activation and Epigenetic Regulation of HSCs Phenotypes

Current Pathobiology Reports

Volumn 2, Issue 4, 2014, Pages 163-170

  Page, Agata ^a   Mann, Derek A ^a   Mann, Jelena ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

DNA methylation; Epigenetics; Hepatic stellate cells; Histone modyfications; Liver fibrosis; MicroRNAs

Indexed keywords

EID: 85034748762     PISSN: None     EISSN: 2167485X     Source Type: Journal    
DOI: 10.1007/s40139-014-0052-0     Document Type: Review

References (74)

1. Olaso E, Friedman SL (1998) Molecular regulation of hepatic fibrogenesis. J Hepatol 29(5):836–847
2. Fallowfield JA, Iredale JP (2004) Targeted treatments for cirrhosis. Expert Opin Ther Targets 8(5):423–435. doi:10.1517/14728222.8.5.423
3. Pinzani M, Rombouts K, Colagrande S (2005) Fibrosis in chronic liver diseases: diagnosis and management. J Hepatol 42(Suppl 1):S22–S36. doi:10.1016/j.jhep.2004.12.008
4. Mederacke I, Hsu CC, Troeger JS, Huebener P, Mu X, Dapito DH et al (2013) Fate tracing reveals hepatic stellate cells as dominant contributors to liver fibrosis independent of its aetiology. Nat Commun 4:2823. doi:10.1038/ncomms3823
5. Friedman SL (2008) Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver. Physiol Rev 88(1):125–172. doi:10.1152/physrev.00013.2007
6. Rippe RA, Brenner DA (2004) From quiescence to activation: gene regulation in hepatic stellate cells. Gastroenterology 127(4):1260–1262
7. Kisseleva T, Cong M, Paik Y, Scholten D, Jiang C, Benner C et al (2012) Myofibroblasts revert to an inactive phenotype during regression of liver fibrosis. Proc Natl Acad Sci USA 109(24):9448–9453. doi:10.1073/pnas.1201840109
8. Ebrahimkhani MR, Oakley F, Murphy LB, Mann J, Moles A, Perugorria MJ et al (2011) Stimulating healthy tissue regeneration by targeting the 5-HT(2)B receptor in chronic liver disease. Nat Med 17(12):1668–1673. doi:10.1038/nm.2490
9. Jenuwein T, Allis CD (2001) Translating the histone code. Science (New York, NY) 293(5532):1074–1080. doi:10.1126/science.1063127
10. Strahl BD, Allis CD (2000) The language of covalent histone modifications. Nature 403(6765):41–45. doi:10.1038/47412
11. Bird A (2007) Perceptions of epigenetics. Nature 447(7143):396–398. doi:10.1038/nature05913
12. Gelato KA, Fischle W (2008) Role of histone modifications in defining chromatin structure and function. Biol Chem 389(4):353–363. doi:10.1515/bc.2008.048
13. Talbert PB, Henikoff S (2006) Spreading of silent chromatin: inaction at a distance. Nat Rev Genet 7(10):793–803. doi:10.1038/nrg1920
14. Richards EJ, Elgin SC (2002) Epigenetic codes for heterochromatin formation and silencing: rounding up the usual suspects. Cell 108(4):489–500
15. Mann J, Chu DC, Maxwell A, Oakley F, Zhu NL, Tsukamoto H et al (2010) MeCP2 controls an epigenetic pathway that promotes myofibroblast transdifferentiation and fibrosis. Gastroenterology. 138(2):705–714. doi:10.1053/j.gastro.2009.10.002 14 e1–4
16. Perugorria MJ, Wilson CL, Zeybel M, Walsh M, Amin S, Robinson S et al (2012) Histone methyltransferase ASH1 orchestrates fibrogenic gene transcription during myofibroblast transdifferentiation. Hepatology (Baltimore, Md) 56(3):1129–1139. doi:10.1002/hep.25754
17. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ (1999) Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 116(6):1413–1419
18. Poynard T, Bedossa P, Opolon P (1997) Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 349(9055):825–832
19. Teli MR, Day CP, Burt AD, Bennett MK, James OF (1995) Determinants of progression to cirrhosis or fibrosis in pure alcoholic fatty liver. Lancet 346(8981):987–990
20. Fischle W, Wang Y, Allis CD (2003) Histone and chromatin cross-talk. Curr Opin Cell Biol 15(2):172–183
21. Lavrov SA, Kibanov MV (2007) Noncoding RNAs and chromatin structure. Biochem Biokhimiia 72(13):1422–1438
22. ∙∙ Zeybel M, Hardy T, Wong YK, Mathers JC, Fox CR, Gackowska A et al (2012) Multigenerational epigenetic adaptation of the hepatic wound-healing response. Nat Med 18(9):1369–77. doi:10.1038/nm.2893. A new provocative research showing that development of liver fibrosis in male rats leads to epigenetic changes in the sperm, which transmit protection from liver fibrosis to their offsprings. The study suggests that population variability may be influenced by environmentally-induced factors transmitted between generations via heritable epigenetic marks
23. Bird A (2002) DNA methylation patterns and epigenetic memory. Genes Dev 16(1):6–21. doi:10.1101/gad.947102
24. Cedar H, Bergman Y (2012) Programming of DNA methylation patterns. Annu Rev Biochem 81:97–117. doi:10.1146/annurev-biochem-052610-091920
25. Tahiliani M, Koh KP, Shen Y, Pastor WA, Bandukwala H, Brudno Y et al (2009) Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science (New York, NY) 324(5929):930–935. doi:10.1126/science.1170116
26. Jones PA, Baylin SB (2007) The epigenomics of cancer. Cell 128(4):683–692. doi:10.1016/j.cell.2007.01.029
27. Nan X, Bird A (2001) The biological functions of the methyl-CpG-binding protein MeCP2 and its implication in Rett syndrome. Brain Dev 23(Suppl 1):S32–S37
28. Hu B, Gharaee-Kermani M, Wu Z, Phan SH (2011) Essential role of MeCP2 in the regulation of myofibroblast differentiation during pulmonary fibrosis. Am J Pathol 178(4):1500–1508. doi:10.1016/j.ajpath.2011.01.002
29. Feng Y, Huang W, Wani M, Yu X, Ashraf M (2014) Ischemic preconditioning potentiates the protective effect of stem cells through secretion of exosomes by targeting Mecp2 via miR-22. PLoS ONE 9(2):e88685. doi:10.1371/journal.pone.0088685
30. Zhou P, Lu Y, Sun XH (2011) Zebularine suppresses TGF-beta-induced lens epithelial cell-myofibroblast transdifferentiation by inhibiting MeCP2. Mol Vis 17:2717–2723
31. Hazra S, She HY, Xiong SG, Rippe RA, Tangkjvanich P, Yee H et al (2001) PPAR gamma regulation of hepatic stellate cells. Hepatology (Baltimore, Md) 34(4):444A–A
32. ∙∙ Mellen M, Ayata P, Dewell S, Kriaucionis S, Heintz N (2012) MeCP2 binds to 5hmC enriched within active genes and accessible chromatin in the nervous system. Cell 151(7):1417–1430. doi:10.1016/j.cell.2012.11.022. The paper presents a new potential role of MeCP2, which is a master epigenetic regulator in liver fibrosis. MeCP2 binds to 5-hydroxymethylcytosine (5hmC), a modification of DNA methylation that may be associated with transcriptionally active genes
33. Mann J, Oakley F, Akiboye F, Elsharkawy A, Thorne AW, Mann DA (2007) Regulation of myofibroblast transdifferentiation by DNA methylation and MeCP2: implications for wound healing and fibrogenesis. Cell Death Differ 14(2):275–285. doi:10.1038/sj.cdd.4401979
34. Tao H, Huang C, Yang JJ, Ma TT, Bian EB, Zhang L et al (2011) MeCP2 controls the expression of RASAL1 in the hepatic fibrosis in rats. Toxicology 290(2–3):327–333. doi:10.1016/j.tox.2011.10.011
35. Yang JJ, Tao H, Huang C, Shi KH, Ma TT, Bian EB et al (2013) DNA methylation and MeCP2 regulation of PTCH1 expression during rats hepatic fibrosis. Cell Signal 25(5):1202–1211. doi:10.1016/j.cellsig.2013.01.005
36. Zheng J, Wu C, Lin Z, Guo Y, Shi L, Dong P et al (2014) Curcumin up-regulates phosphatase and tensin homologue deleted on chromosome 10 through microRNA-mediated control of DNA methylation–a novel mechanism suppressing liver fibrosis. FEBS J 281(1):88–103. doi:10.1111/febs.12574
37. Bechtel W, McGoohan S, Zeisberg EM, Muller GA, Kalbacher H, Salant DJ et al (2010) Methylation determines fibroblast activation and fibrogenesis in the kidney. Nat Med 16(5):544–550. doi:10.1038/nm.2135
38. Yang MD, Chiang YM, Higashiyama R, Asahina K, Mann DA, Mann J et al (2012) Rosmarinic acid and baicalin epigenetically derepress peroxisomal proliferator-activated receptor gamma in hepatic stellate cells for their antifibrotic effect. Hepatology (Baltimore, Md) 55(4):1271–1281. doi:10.1002/hep.24792
39. Chen SL, Zheng MH, Shi KQ, Yang T, Chen YP (2013) A new strategy for treatment of liver fibrosis: letting MicroRNAs do the job. BioDrugs 27(1):25–34. doi:10.1007/s40259-012-0005-2
40. Ambros V (2004) The functions of animal microRNAs. Nature 431(7006):350–355. doi:10.1038/nature02871
41. Krek A, Grun D, Poy MN, Wolf R, Rosenberg L, Epstein EJ et al (2005) Combinatorial microRNA target predictions. Nat Genet 37(5):495–500. doi:10.1038/ng1536
42. He L, Hannon GJ (2004) MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet 5(7):522–531. doi:10.1038/nrg1379
43. Calin GA, Croce CM (2006) MicroRNA signatures in human cancers. Nat Rev Cancer 6(11):857–866. doi:10.1038/nrc1997
44. Venugopal SK, Jiang J, Kim TH, Li Y, Wang SS, Torok NJ et al (2010) Liver fibrosis causes downregulation of miRNA-150 and miRNA-194 in hepatic stellate cells, and their overexpression causes decreased stellate cell activation. Am J Physiol Gastrointest Liver Physiol 298(1):G101–G106. doi:10.1152/ajpgi.00220.2009
45. Guo CJ, Pan Q, Cheng T, Jiang B, Chen GY, Li DG (2009) Changes in microRNAs associated with hepatic stellate cell activation status identify signaling pathways. FEBS J 276(18):5163–5176. doi:10.1111/j.1742-4658.2009.07213.x
46. Wang B, Li W, Guo K, Xiao Y, Wang Y, Fan J (2012) miR-181b promotes hepatic stellate cells proliferation by targeting p27 and is elevated in the serum of cirrhosis patients. Biochem Biophys Res Commun 421(1):4–8. doi:10.1016/j.bbrc.2012.03.025
47. Noetel A, Elfimova N, Altmuller J, Becker C, Becker D, Lahr W et al (2013) Next generation sequencing of the Ago2 interacting transcriptome identified chemokine family members as novel targets of neuronal microRNAs in hepatic stellate cells. J Hepatol 58(2):335–341. doi:10.1016/j.jhep.2012.09.024
48. Wei J, Feng L, Li Z, Xu G, Fan X (2013) MicroRNA-21 activates hepatic stellate cells via PTEN/Akt signaling. Biomed Pharmacother 67(5):387–392. doi:10.1016/j.biopha.2013.03.014
49. Zhang Z, Gao Z, Hu W, Yin S, Wang C, Zang Y et al (2013) 3,3′-Diindolylmethane ameliorates experimental hepatic fibrosis via inhibiting miR-21 expression. Br J Pharmacol 170(3):649–660. doi:10.1111/bph.12323
50. Li ZJ, Ou-Yang PH, Han XP (2014) Profibrotic effect of miR-33a with Akt activation in hepatic stellate cells. Cell Signal 26(1):141–148. doi:10.1016/j.cellsig.2013.09.018
51. Ogawa T, Enomoto M, Fujii H, Sekiya Y, Yoshizato K, Ikeda K et al (2012) MicroRNA-221/222 upregulation indicates the activation of stellate cells and the progression of liver fibrosis. Gut 61(11):1600–1609. doi:10.1136/gutjnl-2011-300717
52. Iizuka M, Ogawa T, Enomoto M, Motoyama H, Yoshizato K, Ikeda K et al (2012) Induction of microRNA-214-5p in human and rodent liver fibrosis. Fibrogenesis Tissue Repair 5(1):12. doi:10.1186/1755-1536-5-12
53. Roderburg C, Mollnow T, Bongaerts B, Elfimova N, Vargas Cardenas D, Berger K et al (2012) Micro-RNA profiling in human serum reveals compartment-specific roles of miR-571 and miR-652 in liver cirrhosis. PloS one 7(3):e32999. doi:10.1371/journal.pone.0032999
54. Li J, Ghazwani M, Zhang Y, Lu J, Li J, Fan J et al (2013) miR-122 regulates collagen production via targeting hepatic stellate cells and suppressing P4HA1 expression. J Hepatol 58(3):522–528. doi:10.1016/j.jhep.2012.11.011
55. Roderburg C, Luedde M, Vargas Cardenas D, Vucur M, Mollnow T, Zimmermann HW et al (2013) miR-133a mediates TGF-beta-dependent derepression of collagen synthesis in hepatic stellate cells during liver fibrosis. J Hepatol 58(4):736–742. doi:10.1016/j.jhep.2012.11.022
56. He Y, Huang C, Sun X, Long XR, Lv XW, Li J (2012) MicroRNA-146a modulates TGF-beta1-induced hepatic stellate cell proliferation by targeting SMAD4. Cell Signal 24(10):1923–1930. doi:10.1016/j.cellsig.2012.06.003
57. Kwiecinski M, Elfimova N, Noetel A, Tox U, Steffen HM, Hacker U et al (2012) Expression of platelet-derived growth factor-C and insulin-like growth factor I in hepatic stellate cells is inhibited by miR-29. Lab Invest 92(7):978–987. doi:10.1038/labinvest.2012.70
58. Lakner AM, Steuerwald NM, Walling TL, Ghosh S, Li T, McKillop IH et al (2012) Inhibitory effects of microRNA 19b in hepatic stellate cell-mediated fibrogenesis. Hepatology (Baltimore, Md) 56(1):300–310. doi:10.1002/hep.25613
59. Cheng K, Yang N, Mahato RI (2009) TGF-beta1 gene silencing for treating liver fibrosis. Mol Pharm 6(3):772–779. doi:10.1021/mp9000469
60. Mercer TR, Dinger ME, Mattick JS (2009) Long non-coding RNAs: insights into functions. Nat Rev Genet 10(3):155–159. doi:10.1038/nrg2521
61. Esteller M (2011) Non-coding RNAs in human disease. Nat Rev Genet 12(12):861–874. doi:10.1038/nrg3074
62. Santos-Rosa H, Caldas C (2005) Chromatin modifier enzymes, the histone code and cancer. Eur J Cancer (Oxford, England: 1990) 41(16):2381–2402. doi:10.1016/j.ejca.2005.08.010
63. Kouzarides T (2007) Chromatin modifications and their function. Cell 128(4):693–705. doi:10.1016/j.cell.2007.02.005
64. Koch CM, Andrews RM, Flicek P, Dillon SC, Karaoz U, Clelland GK et al (2007) The landscape of histone modifications across 1 % of the human genome in five human cell lines. Genome Res 17(6):691–707. doi:10.1101/gr.5704207
65. Ruthenburg AJ, Li H, Patel DJ, Allis CD (2007) Multivalent engagement of chromatin modifications by linked binding modules. Nat Rev Mol Cell Biol 8(12):983–994. doi:10.1038/nrm2298
66. Kramer M, Dees C, Huang J, Schlottmann I, Palumbo-Zerr K, Zerr P et al (2013) Inhibition of H3K27 histone trimethylation activates fibroblasts and induces fibrosis. Ann Rheum Dis 72(4):614–620. doi:10.1136/annrheumdis-2012-201615
67. Miranda TB, Cortez CC, Yoo CB, Liang G, Abe M, Kelly TK et al (2009) DZNep is a global histone methylation inhibitor that reactivates developmental genes not silenced by DNA methylation. Mol Cancer Ther 8(6):1579–1588. doi:10.1158/1535-7163.mct-09-0013
68. Sheen-Chen SM, Lin CR, Chen KH, Yang CH, Lee CT, Huang HW et al (2013) Epigenetic histone methylation regulates transforming growth factor beta-1 expression following bile duct ligation in rats. J Gastroenterol. doi:10.1007/s00535-013-0892-0
69. Wang Q, Wang LX, Zeng JP, Liu XJ, Liang XM, Zhou YB (2013) Histone demethylase retinoblastoma binding protein 2 regulates the expression of alpha-smooth muscle actin and vimentin in cirrhotic livers. Braz J Med Biol Res 46(9):739–745. doi:10.1590/1414-431x20132843
70. Niki T, Rombouts K, De Bleser P, De Smet K, Rogiers V, Schuppan D et al (1999) A histone deacetylase inhibitor, trichostatin A, suppresses myofibroblastic differentiation of rat hepatic stellate cells in primary culture. Hepatology (Baltimore, Md) 29(3):858–867. doi:10.1002/hep.510290328
71. Rombouts K, Niki T, Wielant A, Hellemans K, Geerts A (2001) Trichostatin A, lead compound for development of antifibrogenic drugs. Acta Gastroenterol Belg 64(3):239–246
72. Mannaerts I, Eysackers N, Onyema OO, Van Beneden K, Valente S, Mai A et al (2013) Class II HDAC inhibition hampers hepatic stellate cell activation by induction of microRNA-29. PLoS ONE 8(1):e55786. doi:10.1371/journal.pone.0055786
73. Tiao MM, Wang FS, Huang LT, Chuang JH, Kuo HC, Yang YL et al (2014) MicroRNA-29a protects against acute liver injury in a mouse model of obstructive jaundice via inhibition of the extrinsic apoptosis pathway. Apoptosis 19(1):30–41
74. Guo CJ, Pan Q, Xiong H, Qiao YQ, Bian ZL, Zhong W et al (2013) Dynamic expression of miR-126* and its effects on proliferation and contraction of hepatic stellate cells. FEBS Lett 587(23):3792–3801. doi:10.1016/j.febslet.2013.09.047